GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Maxigen Biotech Inc (TPE:1783) » Definitions » EV-to-Revenue

Maxigen Biotech (TPE:1783) EV-to-Revenue : 5.39 (As of Sep. 21, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Maxigen Biotech EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Maxigen Biotech's enterprise value is NT$3,286.0 Mil. Maxigen Biotech's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was NT$609.2 Mil. Therefore, Maxigen Biotech's EV-to-Revenue for today is 5.39.

The historical rank and industry rank for Maxigen Biotech's EV-to-Revenue or its related term are showing as below:

TPE:1783' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.17   Med: 4.33   Max: 11.28
Current: 5.39

During the past 13 years, the highest EV-to-Revenue of Maxigen Biotech was 11.28. The lowest was 1.17. And the median was 4.33.

TPE:1783's EV-to-Revenue is ranked worse than
70.1% of 826 companies
in the Medical Devices & Instruments industry
Industry Median: 3.15 vs TPE:1783: 5.39

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-09-21), Maxigen Biotech's stock price is NT$42.75. Maxigen Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was NT$6.79. Therefore, Maxigen Biotech's PS Ratio for today is 6.30.


Maxigen Biotech EV-to-Revenue Historical Data

The historical data trend for Maxigen Biotech's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxigen Biotech EV-to-Revenue Chart

Maxigen Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.95 3.02 6.77 5.35 6.22

Maxigen Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.79 7.30 6.22 5.89 5.90

Competitive Comparison of Maxigen Biotech's EV-to-Revenue

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maxigen Biotech's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's EV-to-Revenue falls into.



Maxigen Biotech EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Maxigen Biotech's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3285.964/609.244
=5.39

Maxigen Biotech's current Enterprise Value is NT$3,286.0 Mil.
Maxigen Biotech's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$609.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maxigen Biotech  (TPE:1783) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Maxigen Biotech's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=42.75/6.789
=6.30

Maxigen Biotech's share price for today is NT$42.75.
Maxigen Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$6.79.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maxigen Biotech EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Maxigen Biotech's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Maxigen Biotech Business Description

Traded in Other Exchanges
N/A
Address
No. 88, Keji 1st Rd, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products. It provides medical devices for orthopedic, ophthalmic, dental, and surgical applications. Skincare product categories include mask series, facial cleansing series, and body care series. The biomedical products segment is primarily engaged in the manufacturing and sales of collagen and bone materials, which forms the majority chunk of the revenue of the group. The consumer products segment is engaged in the manufacturing and sales of beauty care products.

Maxigen Biotech Headlines

No Headlines